Mark Levis

36PUBLICATIONS
151CO-AUTHORS
Haematological tumoursCardiovascular medicine and haematology not elsewhere classifiedMedical virologyMolecular targetsQuantum optics and quantum optomechanics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Oct 07, 2026
Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.

|Jul 30, 2026
Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML.

|Jun 04, 2026
ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

|Jun 01, 2026
Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|May 20, 2026
A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

|Apr 08, 2026
Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Mark J Levis, Harry P Erba, Pau Montesinos

Pageof 6

Frequent Collaborators

12 joint publications

Alexander Perl

9 joint publications

Yi-Bin Chen

7 joint publications

Mehdi Hamadani

7 joint publications

Pau Montesinos